Clinical Trial Update: Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating fixed-dose nivolumab (40 mg) in relapsed/refractory Hodgkin lymphoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: St. Petersburg State Pavlov Medical University | Conditions: Hodgkin Lymphoma | Phase 1, Phase 2 | Status: COMPLETED